Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin's Lymphoma
スポンサーリンク
概要
- 論文の詳細を見る
- 2006-08-15
著者
-
CHOU Takaaki
Department of Internal Medicine, Niigata Cancer Center Hospital
-
Chou Takaaki
東海大学 医学部
-
Chou Takaaki
Department Of Internal Medicine Niigata Cancer Center Hospital
-
Chou Takaaki
中華人民共和国
-
CHOU Takaaki
Niigata Cancer Center Hospital
-
IMAI Yosuke
Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology
-
Chou T
Department Of Internal Medicine Niigata Cancer Center Hospital
-
Han Li-na
The First Clinical College Of Harbin Medical University
-
ZHOU Jin
The First Clinical College of Harbin Medical University
-
HIROSE Takayuki
Department of Internal Medicine, Niigata Cancer Center Hospital
-
ISHIGURO Takuro
Department of Internal Medicine, Niigata Cancer Center Hospital
-
Imai Yosuke
Department Of Biotechnology And Life Science Tokyo University Of Agriculture And Technology
-
Imai Yosuke
Department Of Internal Medicine Niigata Cancer Center Hospital
-
Hirose Takayuki
Department Of Internal Medicine Niigata Cancer Center Hospital
-
Ishiguro Takuro
Department Of Internal Medicine Niigata Cancer Center Hospital
関連論文
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma : Results from the Japan Myeloma Study Group
- Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208
- Phase II Study of Cladribine(2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma
- Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
- A Low Invasive Gene Transfer to a Single Cell Using Nanoneedle Operated by AFM
- 2P564 A low invasive and high efficient gene delivery method into a single cell using nanoneedle and AFM(53. Bioengineering,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)
- Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
- Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin's Lymphoma
- B-70. Mechanics of Cervical Syndrome
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases : a multi-institutional study
- Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma : a single center experience
- Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma
- Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95
- Multiple Myeloma : Recent Progress in Diagnosis and Treatment